Squarepoint
ANRO icon

Squarepoint’s Alto Neuroscience ANRO Stock Holding History

Squarepoint’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$562K Sell
21,286
-8,675
-29% -$201K ﹤0.01% 3346
2026
Q1 		$674K Buy
+29,961
New +$555K ﹤0.01% 3101
2025
Q4 		– Sell
-22,816
Closed -$91.7K – 5011
2025
Q3 		$91.7K Sell
22,816
-45,132
-66% -$150K ﹤0.01% 4129
2025
Q2 		$149K Buy
67,948
+51,384
+310% +$122K ﹤0.01% 4063
2025
Q1 		$35.8K Buy
+16,564
New +$59.3K ﹤0.01% 4389
2024
Q2 		– Sell
-28,369
Closed -$435K – 4744
2024
Q1 		$435K Buy
+28,369
New +$444K ﹤0.01% 3139

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Squarepoint's ANRO Position: Q2 2026 in Review

Squarepoint reduced its Alto Neuroscience (ANRO) stake by 29% in Q2 2026, selling an estimated $201K and leaving 21,286 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #3346.

Squarepoint first reported a position in ANRO in Q1 2024 and has held it in 6 quarters since. The position peaked at $674K in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Squarepoint held 21,286 shares of Alto Neuroscience worth $562K as of Q2 2026.
  • Squarepoint sold 8,675 Alto Neuroscience shares in Q2 2026, an estimated $201K.
  • Alto Neuroscience made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3346 holding.
  • Squarepoint first reported a position in Alto Neuroscience in Q1 2024 and has held it in 6 quarters since.
  • Squarepoint's Alto Neuroscience position peaked at $674K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.